Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
Esperion Therapeutics has finalized the acquisition of Corstasis Therapeutics, incorporating the FDA-approved Enbumyst nasal spray loop diuretic into its cardiovascular portfolio. This addition expands Esperion's treatment offerings for edema related to congestive heart failure and other conditions, enhancing outpatient care options and supporting …